Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer

Clinical trial NCT05227131 · WITHDRAWN

Trial details

NCT number: NCT05227131
Sponsor: MedSIR
Status: WITHDRAWN
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Breast Cancer Advanced Breast Cancer HER2-positive Breast Cancer

Start date: 2022-05-15
Primary completion: 2024-10-01
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.